Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
43 results about "Noribogaine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Noribogaine (actually O-desmethylibogaine), or 12-hydroxyibogamine, is the principal psychoactive metabolite of the oneirogen ibogaine. It is thought to be involved in the antiaddictive effects of ibogaine-containing plant extracts, such as Tabernanthe iboga.
Noribogaine in the treatment of pain and drug addiction
InactiveUS7220737B1Eliminate symptomsConveniently preparedBiocideAnimal repellantsOpioid antagonistTreatment pain
The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.
Owner:DEMERX
Method of treating chemical dependency in mammals and a composition therefor
An essentially pure noribogaine compound having the formula: wherein R is hydrogen or a hydrolyzable group of the formula: wherein X is an unsubstituted C1-C12 group or a C1-C12 group substituted by lower alkyl or lower alkoxy groups, wherein the noribogaine compound having the hydrolyzable group hydrolyzes in vivo to form 12-hydroxy ibogamine.
Owner:MASH DEBORAH C +2
Noribogaine in the treatment of pain and drug addiction
InactiveUS7754710B2Eliminate symptomsConveniently preparedBiocideNervous disorderOpioid antagonistMedicine
The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.
Owner:DEMERX
N-substituted noribogaine prodrugs
InactiveUS8741891B1Reduce systemic circulationImprove concentrationBiocideOrganic chemistryStereochemistryNoribogaine
This invention relates generally to prodrugs of noribogaine. This invention also relates to pharmaceutical compositions comprising the prodrugs of noribogaine as well as method of treating pain, addiction and / or stress using such compounds and / or pharmaceutical compositions.
Owner:DEMERX
Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
InactiveUS20060229293A1Treating hepatitis CImprove the level ofBiocideCarbohydrate active ingredientsMetaboliteChronic hepatitis
The present invention pertains to a composition comprising Ibogaine, an indole alkaloid, its active salts and its principal metabolite noribogaine, a demethylated form of ibogaine, for the treatment of hepatitis C and hepatitis C related complications, administered in single or multiple dose regimens effective to reduce somatic complaints, liver enzyme values and viral load caused by chronic hepatitis C in patients, and methods of using the same.
Owner:ADDICTION RES INST INC
Methods and compositions for preparing noribogaine from voacangine
ActiveUS20130303756A1Minimize contaminationEliminate pollutionOrganic chemistryBulk chemical productionCombinatorial chemistryNoribogaine
Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.
Owner:DEMERX
Noribogaine compositions
Disclosed are noribogaine compositions comprising a very high level of the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer and not more than 0.5 wt % of ibogaine relative to the total amount of noribogaine.
Owner:DEMERX
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
ActiveUS8637648B1Increase in cranial concentrationReduce deliverySugar derivativesExcipientPharmaceutical preservatives
This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.
Owner:DEMERX
Stereoselective total synthesis of noribogaine
This invention relates generally to methods for synthesizing the non-addictive alkaloid noribogaine.
Owner:DEMERX
N-substituted noribogaine prodrugs
ActiveUS20140315891A1Reduce systemic circulationImprove concentrationBiocideOrganic chemistryPharmaceutical SubstancesMedicinal chemistry
This invention relates generally to prodrugs of noribogaine. This invention also relates to pharmaceutical compositions comprising the prodrugs of noribogaine as well as method of treating pain, addiction and / or stress using such compounds and / or pharmaceutical compositions.
Owner:DEMERX
Methods and compositions for preparing noribogaine from voacangine
Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.
Owner:DEMERX
Noribogaine in the treatment of pain and drug addiction
InactiveUS20070185085A1Eliminate symptomsConveniently preparedBiocideNervous disorderOpioid antagonistTreatment pain
The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.
Owner:DEMERX
Methods for acute and long-term treatment of substance abuse
This invention is directed to a method of treating drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine or a pharmaceutically acceptable salt and / or solvate thereof at a dosage that provides a therapeutic serum concentration. In one embodiment, the average serum concentration is 50 ng / mL to 180 ng / mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds, and preferably about 30 milliseconds.
Owner:DEMERX
Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
ActiveUS20150238503A1Reduce smokeIncrease volumeBiocidePharmaceutical delivery mechanismPharmacologyNoribogaine
This invention provides methods and compositions for treating nicotine addiction or treating or preventing nicotine cravings in a subject. The method comprises administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof.
Owner:DEMERX
Use of noribogaine for the treatment of pain
InactiveUS20150258104A1Alleviate and inhibit painBiocideAnimal repellantsSerum concentrationQT interval
This invention is directed to methods of treating pain in patients comprising treating patients with noribogaine at a dosage that provides an average serum concentration of 50 ng / mL to 180 ng / mL, including under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
Owner:DEMERX
Methods and compositions for reducing tolerance to opioid analgesics
InactiveUS20150258108A1Effective analgesiaReduced Tolerance RequirementsBiocideAnimal repellantsSerum concentrationTolerability
A method for modulating tolerance to an opioid analgesic in a patient undergoing opioid analgesic therapy, the method comprising interrupting or administering concurrently with said opioid analgesic therapy an amount of noribogaine, noribogaine derivative, or pharmaceutically acceptable salt and / or solvate thereof that provides a therapeutic serum concentration of noribogaine. In some embodiments, the therapeutic average serum concentration is 50 ng / mL to 180 ng / mL, said concentration being sufficient to re-sensitize the patient to the opioid as an analgesic while maintaining a QT interval of less than about 500 ms during said treatment.
Owner:DEMERX
Method for noribogaine treatment in patients on methadone
ActiveUS20150045350A1Alleviate withdrawal symptomsExtension of timeBiocideNervous disorderShort term treatmentSide effect
A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment.
Owner:DEMERX
Methods and compositions for sustained noribogaine treatment
This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of 50 ng / mL to 180 ng / mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
Owner:DEMERX
Methods and compositions for treating depression
InactiveUS20150258107A1Relieve symptomsIncrease volumeBiocideAnimal repellantsPsychiatryPosttraumatic stress disorders
This invention provides a method for treating depression and / or posttraumatic stress disorder in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt and / or solvate thereof.
Owner:DEMERX
Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
Provided herein are indole and benzofuran fused isoquinuclidene derivatives. Also provided herein are processes, preferably enantioselective processes, for preparing such derivatives including processes for preparing (−) and (+) noribogaine or a salt thereof, in substantially enantiomerically pure forms.
Owner:DEMERX
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
InactiveUS8802832B2Increase in cranial concentrationReduce deliveryNervous disorderSugar derivativesPharmacologyPharmaceutical preservatives
Owner:DEMERX
Methods for acute and long-term treatment of drug addiction
InactiveUS20150231147A1Ameliorate most significant withdraw symptomPrevent relapseHeterocyclic compound active ingredientsSerum concentrationQT interval
This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of about 50 ng / mL to about 180 ng / mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
Owner:DEMERX
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
InactiveUS20140113878A1Raise the possibilityIncrease in cranial concentrationBiocideNervous disorderExcipientPharmaceutical preservatives
This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.
Owner:DEMERX
N-substituted noribogaine prodrugs
This invention relates generally to prodrugs of noribogaine. This invention also relates to pharmaceutical compositions comprising the prodrugs of noribogaine as well as method of treating pain, addiction and / or stress using such compounds and / or pharmaceutical compositions.
Owner:DEMERX
Methods for acute and long-term treatment of drug addiction
InactiveUS20180280406A1Increase in time to resumptionRelieve symptomsHeterocyclic compound active ingredientsSerum concentrationQT interval
Owner:DEMERX
Methods and compositions for treating impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
InactiveUS20160038505A1Reduce controlRelieve symptomsBiocideAnimal repellantsPharmacyControl disorders
This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and / or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt and / or solvate thereof.
Owner:DEMERX
Medicinal Composition for Treating Symptoms Related to Parkinson's Disease
InactiveUS20160331759A1Pharmaceutical non-active ingredientsHeterocyclic compound active ingredientsGlial cell line-derived neurotrophic factorJuvenile parkinson's disease
A medicinal composition is administered orally twice a day to a patient to ameliorate the symptoms related to Parkinson's disease. The medicinal composition includes mixing a quantity of ibogaine, a quantity of vitamin supplements and a quantity of manufacturing additives into a heterogeneous medicinal mixture. The quantity of ibogaine, formulated as ibogaine HCl, other non-toxic salts of ibogaine (an alkaloid of the family apocynaceae), or noribogaine, its active metabolite, is an active ingredient to regulate endogenous glial cell line-derived neurotrophic factor (GDNF). The quantity of vitamin supplements promotes the general health and neurological functions. The quantity of manufacturing additives bonds the quantity of ibogaine and the quantity of vitamin supplements together, as well as, provides anti-adherent properties to prevent the medicinal mixture from adhering to manufacturing equipment.
Owner:PHYTOSTAN INT INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com